Critical Care & Emergencies (all articles)
RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.
5 Oct, 2021 | 10:06h | UTCRelated:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
5 Oct, 2021 | 09:57h | UTCA Pill For COVID? | A Doctor Explains Molnupiravir – ZDoggMD
Merck’s Covid-19 pill is great news but may not be a game-changer.
5 Oct, 2021 | 09:59h | UTCMerck’s Covid-19 pill is great news but may not be a game-changer – CNN
AHA Scientific Statement: Diagnosis and management of patients with myocardial injury after noncardiac surgery.
5 Oct, 2021 | 09:01h | UTCNews Release: 1 in 5 adults has high levels of heart enzymes after any surgery, monitoring advised – American Heart Association
Commentary: AHA: More Screening Needed to Catch Myocardial Injury After Noncardiac Surgery – TCTMD
Intra-abdominal hypertension and abdominal compartment syndrome in critically ill patients: A narrative review of past, present, and future steps.
5 Oct, 2021 | 08:52h | UTC
Review: Optimizing care for critically ill older adults.
5 Oct, 2021 | 08:51h | UTCOptimizing care for critically ill older adults – Canadian Medical Association Journal
[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.
3 Oct, 2021 | 23:02h | UTCCommentaries:
Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre
Covid antiviral pill can halve risk of hospitalization – BBC
Why Merck’s Covid-19 pill molnupiravir could be so important – Vox
Commentaries on Twitter
.@DrEricDing convinced many that stopping the #molnupiravir trial early for benefit was a good idea
But it was NOT
Large body of evidence suggests that stopping early for benefit biases the results: overestimates the benefits of the treatment #EBM https://t.co/b3tHEtliO0 https://t.co/LwuCgqcY0C pic.twitter.com/vyPWc0nd37
— Kari Tikkinen (@KariTikkinen) October 2, 2021
(thread – click for more)
💡BREAKING—New oral anti-viral drug *molnupiravir* cuts risk of #COVID19 hospitalization and death **in HALF** in a randomized trial. Results so astounding that the trial is being stopped early, and Merck plans to apply for emergency authorization ASAP. 🧵 https://t.co/g8JGNzvuRg pic.twitter.com/K1SwC3QFXS
— Eric Feigl-Ding (@DrEricDing) October 1, 2021
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
3 Oct, 2021 | 22:59h | UTCVaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance – The BMJ
Original Guidance: NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Related:
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.
3 Oct, 2021 | 22:41h | UTC
Intensive care triage under exceptional resource scarcity.
3 Oct, 2021 | 22:48h | UTCIntensive care triage under exceptional resource scarcity – Swiss Medical Weekly
RCT: Early computed tomography coronary angiography in patients with suspected acute coronary syndrome did not improve one year clinical outcomes.
3 Oct, 2021 | 22:35h | UTC
Commentary on Twitter
In this RCT, early CT coronary angiography in the emergency department for patients with suspected / provisional diagnosis of acute coronary syndrome had no effect on rate of death or subsequent non-fatal #heartattack at 1 year.@bmj_latest #Wondrmedicalhttps://t.co/usNKEGPDa4
— Prof Chris P Gale (@cpgale3) October 1, 2021
Oral health care for the critically ill: a narrative review.
3 Oct, 2021 | 22:25h | UTCOral health care for the critically ill: a narrative review – Critical Care
International registry shows mortality after ECMO for patients with COVID-19 worsened during 2020.
1 Oct, 2021 | 10:43h | UTCCommentaries:
ECMO in COVID-19: do not blame the tool – The Lancet
Commentary on Twitter (thread – click for more)
New study indicates mortality after ECMO for patients with #COVID19 worsened during 2020, and duration of ECMO support increased.
Continued surveillance of ECMO outcomes in #COVID19 is needed, authors suggest: https://t.co/9Yq7lYkVIC
(1/2) @ELSOOrg pic.twitter.com/Rcz1TZ7eGG
— The Lancet (@TheLancet) September 30, 2021
Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.
1 Oct, 2021 | 10:35h | UTC
WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections.
1 Oct, 2021 | 10:24h | UTCRelated:
Fire safety and emergency evacuation guidelines for intensive care units and operating theatres: for use in the event of fire, flood, power cut, oxygen supply failure, noxious gas, structural collapse or other critical incidents.
1 Oct, 2021 | 10:15h | UTC
Cardiac troponin and defining myocardial infarction.
1 Oct, 2021 | 10:11h | UTCCardiac troponin and defining myocardial infarction – Cardiovascular Research
Doctor’s new first aid technique can stem blood loss after shark attack.
1 Oct, 2021 | 10:03h | UTCDoctor’s ‘brilliant’ new first aid technique can stem blood loss after shark attack – The Guardian
RCT: REGEN-COV antibody combination reduces hospitalizations in outpatients with Covid-19.
30 Sep, 2021 | 10:33h | UTC
Review: Clinical features, laboratory, and radiological findings of patients with acute inflammatory myelopathy after COVID-19 infection.
30 Sep, 2021 | 10:27h | UTC
RCT: Vasopressin + Methylprednisolone increase the likelihood of return of spontaneous circulation compared to placebo in patients with in-hospital cardiac arrest.
30 Sep, 2021 | 10:23h | UTCEffect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Vasopressin and Steroids as Adjunctive Treatment for In-Hospital Cardiac Arrest (free for a limited period)
Commentary on Twitter
Randomized trial among patients with in-hospital cardiac arrest found that administration of vasopressin and methylprednisolone, compared with placebo, significantly increased the likelihood of return of spontaneous circulation https://t.co/wfyl56wgpT pic.twitter.com/LjKoxx8Rav
— JAMA (@JAMA_current) September 29, 2021
Supplement: Acute Respiratory Distress Syndrome.
30 Sep, 2021 | 10:03h | UTCHomepage: Acute Respiratory Distress Syndrome – Critical Care Clinics
The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019
Toward Optimal Acute Respiratory Distress Syndrome Outcomes
Pathophysiology of Acute Respiratory Distress Syndrome and COVID-19 Lung Injury
COVID-19–Associated Acute Respiratory Distress Syndrome
Pathophysiology of the Acute Respiratory Distress Syndrome
Acute Kidney Injury and Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Fluid Therapy and Acute Respiratory Distress Syndrome
Pharmacologic Treatments for Acute Respiratory Distress Syndrome
Long-Term Outcomes in Acute Respiratory Distress Syndrome
Related:
Position paper: Advancing precision medicine for acute respiratory distress syndrome.
Review: Personalized mechanical ventilation in acute respiratory distress syndrome.
Seminar | Acute respiratory distress syndrome.
ARDS: Contemporary management and novel approaches during COVID-19
EM Cases: Liver Emergencies – Acute liver failure, hepatic encephalopathy, hepatorenal syndrome, liver test interpretation & drugs to avoid.
30 Sep, 2021 | 10:04h | UTC
M-A: Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients.
29 Sep, 2021 | 10:24h | UTC
AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.
29 Sep, 2021 | 10:07h | UTCSee also: AGA Technical Review on Coagulation in Cirrhosis – Gastroenterology